Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
11 Jan 2020
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.

Clinical pharmacist specialists may aid in drug therapy management of HCV-infected patients

02 Dec 2019
Clinical pharmacists ought to receive their well-deserved specialist status, and be recognised as an asset to the healthcare team.

Utilizing a clinical pharmacist specialist in a hepatitis C virus (HCV) treatment clinic may help improve drug therapy management of HCV-infected patients treated with direct-acting antivirals (DAAs), suggests a recent study.

A total of 132 patients were managed by a clinical pharmacist specialist. Of these, 87 (66 percent) were treated with ledipasvir/sofosbuvir, 29 (22 percent) with paritaprevir/ritonavir/ombitasvir plus dasabuvir, and 16 (12 percent) with sofosbuvir-based regimen. These treatments showed a sustained virologic response (SVR) rate of 92 percent (n=80), 100 percent (n=29) and 93.8 percent (n=15), respectively.

The SVR rate achieved was 94 percent against HCV genotype 1 (GT-1) and 100 percent against GT-2 to GT-4. The overall SVR rate was 94 percent across regimens: 93 percent in treatment-naïve patients, 96 percent in treatment-experienced patients, 93 percent in noncirrhotic patients and 94 percent in compensated cirrhotic patients.

These results were similar to those reported in pivotal trials for DAAs, according to the authors.

In this study, a clinical pharmacist-managed HCV treatment clinic in treating HCV-infected veterans with DAAs was established under a collaborative practice agreement with infectious disease physicians. Participating veterans were treated between 1 November 2014 and 30 November 2015.

To evaluate SVR after 12 weeks of treatment, the clinical pharmacist specialist engaged in the following activities: pretreatment screening, drug selection, patient education, medication counselling, drug therapy monitoring, drug utilization review, addressing issues on drug adherence, and routine and post-treatment follow-up of patients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
11 Jan 2020
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.